Candel Therapeutics Stock Performance
| CADL Stock | USD 4.71 0.24 4.85% |
The firm shows a Beta (market volatility) of 0.48, which signifies possible diversification benefits within a given portfolio. As returns on the market increase, Candel Therapeutics' returns are expected to increase less than the market. However, during the bear market, the loss of holding Candel Therapeutics is expected to be smaller as well. At this point, Candel Therapeutics has a negative expected return of -0.35%. Please make sure to confirm Candel Therapeutics' maximum drawdown, daily balance of power, period momentum indicator, as well as the relationship between the skewness and day typical price , to decide if Candel Therapeutics performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
0 of 100
Weak | Strong |
Very Weak
Over the last 90 days Candel Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unsteady performance in the last few months, the Stock's fundamental indicators remain quite persistent which may send shares a bit higher in January 2025. The latest mess may also be a sign of long-standing up-swing for the company institutional investors. ...more
| Begin Period Cash Flow | 70.3 M |
Candel |
Candel Therapeutics Relative Risk vs. Return Landscape
If you would invest 631.00 in Candel Therapeutics on September 3, 2024 and sell it today you would lose (160.00) from holding Candel Therapeutics or give up 25.36% of portfolio value over 90 days. Candel Therapeutics is currently does not generate positive expected returns and assumes 4.6508% risk (volatility on return distribution) over the 90 days horizon. In different words, 41% of stocks are less volatile than Candel, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Candel Therapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Candel Therapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Candel Therapeutics, and traders can use it to determine the average amount a Candel Therapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.0761
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | CADL |
Estimated Market Risk
| 4.65 actual daily | 41 59% of assets are more volatile |
Expected Return
| -0.35 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.08 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Candel Therapeutics is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Candel Therapeutics by adding Candel Therapeutics to a well-diversified portfolio.
Candel Therapeutics Fundamentals Growth
Candel Stock prices reflect investors' perceptions of the future prospects and financial health of Candel Therapeutics, and Candel Therapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Candel Stock performance.
| Return On Equity | -4.81 | ||||
| Return On Asset | -0.52 | ||||
| Current Valuation | 152.26 M | ||||
| Shares Outstanding | 32.48 M | ||||
| Price To Book | 30.41 X | ||||
| Price To Sales | 436.42 X | ||||
| Revenue | 31 K | ||||
| EBITDA | (37.43 M) | ||||
| Cash And Equivalents | 86.78 M | ||||
| Cash Per Share | 3.00 X | ||||
| Total Debt | 22.76 M | ||||
| Debt To Equity | 0.38 % | ||||
| Book Value Per Share | 0.44 X | ||||
| Cash Flow From Operations | (34.24 M) | ||||
| Earnings Per Share | (1.73) X | ||||
| Total Asset | 41.2 M | ||||
| Retained Earnings | (137.03 M) | ||||
About Candel Therapeutics Performance
By examining Candel Therapeutics' fundamental ratios, stakeholders can obtain critical insights into Candel Therapeutics' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Candel Therapeutics is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Candel Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the development immunotherapies for the cancer patients. The company was incorporated in 2003 and is based in Needham, Massachusetts. Candel Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 65 people.Things to note about Candel Therapeutics performance evaluation
Checking the ongoing alerts about Candel Therapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Candel Therapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Candel Therapeutics generated a negative expected return over the last 90 days | |
| Candel Therapeutics has high historical volatility and very poor performance | |
| Candel Therapeutics has a very high chance of going through financial distress in the upcoming years | |
| The company reported the previous year's revenue of 31 K. Net Loss for the year was (37.94 M) with loss before overhead, payroll, taxes, and interest of (20.66 M). | |
| Candel Therapeutics currently holds about 86.78 M in cash with (34.24 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 3.0. | |
| Roughly 30.0% of the company shares are held by company insiders |
- Analyzing Candel Therapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Candel Therapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Candel Therapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Candel Therapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Candel Therapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Candel Therapeutics' stock. These opinions can provide insight into Candel Therapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Check out Trending Equities to better understand how to build diversified portfolios, which includes a position in Candel Therapeutics. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices. For more information on how to buy Candel Stock please use our How to buy in Candel Stock guide.You can also try the CEOs Directory module to screen CEOs from public companies around the world.
Is Pharmaceutical Products space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Candel Therapeutics. If investors know Candel will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Candel Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Candel Therapeutics is measured differently than its book value, which is the value of Candel that is recorded on the company's balance sheet. Investors also form their own opinion of Candel Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Candel Therapeutics' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Candel Therapeutics' market value can be influenced by many factors that don't directly affect Candel Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Candel Therapeutics' value and its price as these two are different measures arrived at by different means. Investors typically determine if Candel Therapeutics is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Candel Therapeutics' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.